Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | LPL | P06858 | 1/20 | 0.46 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | F11 | P03951 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2800935 | 0.87 | MAPT (0.56) | MAPTKMT2AROCK1LPLLIPG | |
| SCHEMBL17619412 | 0.85 | HSD11B1 (0.59) | MAPTKMT2AHTTROCK1LPL | |
| SCHEMBL2801560 | 0.85 | ROCK1 (0.44) | MAPTKMT2AROCK1LPLLIPG | |
| SCHEMBL2801562 | 0.85 | ROCK1 (0.44) | MAPTKMT2AROCK1LPLLIPG | |
| SCHEMBL9888311 | 0.83 | MAPT (0.49) | MAPTKMT2AHTTL3MBTL1HDAC4 | |
| SCHEMBL5907498 | 0.81 | FKBP1A (0.64) | MAPTKMT2AHTTL3MBTL1SMN1; SMN2 | |
| SCHEMBL2800316 | 0.81 | ROCK1 (0.71) | MAPTKMT2AHTTROCK1HDAC6 | |
| SCHEMBL15879483 | 0.81 | ROCK1 (0.68) | ROCK1LPLLIPGF11 | |
| SCHEMBL22233270 | 0.80 | ALDH1A1 (0.47) | KMT2AHTTROCK1LPLLIPG | |
| SCHEMBL951497 | 0.80 | PHGDH (0.55) | MAPTKMT2AHTTL3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2941425-B1 | AMINOPYRIDINE DERIVED COMPOUNDS AS LRRK2 INHIBITORS | H LUNDBECK AS (DK) | 2017-07-12 | — | — | EP | disclosed |
| EP-2941425-B1 | AMINOPYRIDINE DERIVED COMPOUNDS AS LRRK2 INHIBITORS | H LUNDBECK AS (DK) | 2017-07-12 | — | — | EP | disclosed |
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9393248-B1 | Aminopyridine derived compounds as LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2016-07-19 | — | — | US | disclosed |
| US-9393248-B1 | Aminopyridine derived compounds as LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2016-07-19 | — | — | US | disclosed |
| US-9393248-B1 | Aminopyridine derived compounds as LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2016-07-19 | — | — | US | disclosed |
| US-20160184317-A1 | Aminopyridine Derived Compounds as LRRK2 Inhibitors | H. LUNDBECK A/S (DK) | 2016-06-30 | — | — | US | disclosed |
| US-20160184317-A1 | Aminopyridine Derived Compounds as LRRK2 Inhibitors | H. LUNDBECK A/S (DK) | 2016-06-30 | — | — | US | disclosed |
| US-20160184317-A1 | Aminopyridine Derived Compounds as LRRK2 Inhibitors | H. LUNDBECK A/S (DK) | 2016-06-30 | — | — | US | disclosed |
| US-8193189-B2 | Quinoxaline derivatives as tyrosine kinase activity inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-20120040936-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| US-20120040936-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| US-20120040936-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| EP-2418203-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | Daiichi Sankyo Company, Limited (JP) | 2012-02-15 | — | — | EP | disclosed |
| EP-2418203-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | Daiichi Sankyo Company, Limited (JP) | 2012-02-15 | — | — | EP | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
| WO-2008148867-A2 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | NOVARTIS AG (CH) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040936-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | BMP2, BMP4, BMP6 | MAPT 4571/4885KMT2A 2350/4885HTT 4631/4885 |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | JAK2, JAK1, JAK3 | MAPT 4677/4885KMT2A 813/4885HTT 2457/4885 |
| US-20160184317-A1 | Aminopyridine Derived Compounds as LRRK2 Inhibitors | LRRK2, PARK7, SNCA | MAPT 9/4885KMT2A 313/4885HTT 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.